Does the intranasal recombinant erythropoietin (NeuralCIM) improve cognitive function in adults ≥ 50 years with mild‑to‑moderate Alzheimer’s disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Does NeuralCIM Intranasal Spray Help Dementia?

Based on the highest quality recent evidence, intranasal NeuroEPO (NeuralCIM®) significantly improves cognitive function in mild-to-moderate Alzheimer's disease and should be considered as a treatment option for these patients.

Critical Evidence Analysis

The FDA drug label 1 describes NeuralCIM as a homeopathic topical product for nerve pain—this is NOT the same product as the intranasal recombinant erythropoietin (NeuroEPO plus/NeuralCIM®) studied in clinical trials. This is a critical distinction: the homeopathic topical product has no proven efficacy for dementia and should not be confused with the investigational intranasal erythropoietin formulation.

Clinical Trial Evidence for Intranasal NeuroEPO (NeuralCIM®)

Primary Evidence: Phase 2-3 RCT (2023)

The ATHENEA trial 2 provides the strongest evidence:

  • Study Design: Double-blind, randomized, placebo-controlled trial in 170 patients ≥50 years with mild-to-moderate AD
  • Intervention: Intranasal NeuroEPO 0.5mg or 1.0mg three times weekly for 48 weeks
  • Primary Outcome (ADAS-Cog11):
    • 0.5mg group: -3.0 points (improvement)
    • 1.0mg group: -4.0 points (improvement)
    • Placebo: +4.0 points (worsening)
    • Difference vs placebo: 7-8 points (p<0.001)
  • Secondary Outcomes: Significant improvements in CIBIC+, GDS, MoCA, NPI, and brain perfusion
  • Safety: Very good safety profile with 85% trial completion

Long-Term Follow-Up Data (2025)

The post-trial observational study 3 at 96 weeks showed:

  • Continued treatment group: -6.0 ADAS-Cog11 change (sustained benefit)
  • Control group: +11.0 ADAS-Cog11 change (progressive decline)
  • Difference: 21.0 points (95% CI: 14.6-27.4, p<0.001)
  • Patients who stopped treatment after initial trial showed cognitive decline, suggesting disease-modifying potential

Mechanism and Rationale

NeuroEPO is a recombinant erythropoietin with low sialic acid content that:

  • Lacks hematopoietic activity (no blood effects)
  • Has shorter plasma half-life
  • Crosses blood-brain barrier via intranasal delivery
  • Prevents oxidative damage, neuroinflammation, and apoptosis in AD models 2
  • Shows upregulation of EPO receptors in affected brain regions 4

Clinical Context: Comparison to Standard Therapies

Standard cholinesterase inhibitors (donepezil, galantamine, rivastigmine) show 5:

  • Small cognitive improvements (ADAS-Cog changes of 2-3 points)
  • Clinically significant global assessment changes (CIBIC-plus)
  • Limited functional benefit
  • Primarily symptomatic, not disease-modifying
  • GI side effects common

NeuroEPO's 7-8 point ADAS-Cog improvement substantially exceeds the 4-point threshold for clinical significance and surpasses standard therapies.

Important Caveats and Limitations

  1. Product Confusion: The homeopathic topical "NeuralCIM" sold in the US 1 is NOT the same as investigational intranasal NeuroEPO (NeuralCIM®) from clinical trials
  2. Limited Geographic Availability: Clinical trial data comes primarily from Cuban studies; broader international validation needed
  3. Sample Size: While statistically robust, larger multicenter trials are warranted 4
  4. Study Duration: Most data limited to 48-96 weeks; longer-term outcomes unknown
  5. Population: Studied specifically in mild-to-moderate AD; efficacy in severe AD or other dementias unclear

Clinical Recommendation Algorithm

For patients with mild-to-moderate Alzheimer's disease:

  1. If intranasal NeuroEPO (NeuralCIM®) is available: Consider as first-line or add-on therapy given superior efficacy data

    • Dose: 0.5-1.0mg intranasally three times weekly
    • Monitor: ADAS-Cog or MMSE at 12-week intervals
    • Continue if cognitive stabilization or improvement observed

  2. If NeuroEPO unavailable: Use standard cholinesterase inhibitors (donepezil, galantamine, rivastigmine) per established guidelines 6, 5

    • Particularly beneficial in rapid cognitive decline (≥3 MMSE points/6 months) 6

  3. Do NOT use: Homeopathic topical "NeuralCIM" products for dementia—these lack evidence and are indicated only for peripheral neuropathy symptoms 1

Safety Profile

NeuroEPO shows excellent tolerability 2:

  • No hematopoietic effects (no polycythemia risk)
  • Minimal adverse events
  • 85% trial completion rate
  • No significant safety concerns in systematic reviews 4

This contrasts favorably with cholinesterase inhibitors' dose-related GI side effects 5.

References

Related Questions

What is the appropriate outpatient workup for bilateral lower leg edema in a patient with normal brain natriuretic peptide (BNP), normal chest X‑ray without pulmonary edema, and normal electrocardiogram (EKG)?
Can Pulmoclear be used to treat a cold‑related productive cough in an adult without known drug allergies?
In a patient with a BMI of 37.6 presenting with an intertriginous rash beneath the abdomen, what diagnoses should be considered?
Can N‑acetylcysteine (acetylcysteine) and acebrophylline be used together in an adult without hepatic or renal impairment, and what are the appropriate dosages, duration, and monitoring recommendations?
In a patient who attempted suicide by ingesting multiple controlled substances, should they be taken to a medical emergency department for acute medical stabilization or directly to a psychiatric emergency service?
In an 18-year-old patient with right lower quadrant (RLQ) pain, does administering iodinated contrast for an abdominal CT pose a risk of liver injury, or should the scan be performed without contrast?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.